215 related articles for article (PubMed ID: 9123162)
1. Critical evaluation of the association of acute with chronic graft rejection in kidney and heart transplant recipients. The Collaborative Transplant Study.
Opelz G
Transplant Proc; 1997; 29(1-2):73-6. PubMed ID: 9123162
[No Abstract] [Full Text] [Related]
2. Medium-term outcome of tacrolimus immunosuppression following rejection or graft dysfunction in heart transplant patients.
Marcus N; Khaghani A; Burke M; Yacoub M; Banner N
Transplant Proc; 1998 Jun; 30(4):1134-5. PubMed ID: 9636460
[No Abstract] [Full Text] [Related]
3. Long-term outcome with the use of OKT3 induction therapy in heart transplant patients: a single-center experience.
Adamson R; Obispo E; Dychter S; Dembitsky W; Moreno-Cabral R; Jaski B; Gordon J; Hoagland P; Moore K; King J; Andrews J; Rich M; Daily PO
Transplant Proc; 1998 Jun; 30(4):1107-9. PubMed ID: 9636449
[No Abstract] [Full Text] [Related]
4. Long-term results of OKT3-treated renal transplant recipients.
Tanabe K; Takahashi K; Sonda K; Tokumoto T; Koga S; Nakazawa H; Goya N; Yagisawa T; Fuchinoue S; Kawai T; Toma H; Ota K
Transplant Proc; 1996 Jun; 28(3):1350-1. PubMed ID: 8658689
[No Abstract] [Full Text] [Related]
5. Antibody therapy in steroid-resistant rejection.
Waiser J; Budde K; Schreiber M; Böhler T; Löbermann LA; Neumayer HH
Transplant Proc; 1998 Aug; 30(5):1778-9. PubMed ID: 9723279
[No Abstract] [Full Text] [Related]
6. Evaluation of various immunosuppressive regimes in second renal transplants.
Toronyi E; Remport A; Járay J; Máthé Z; Borka P; Perner F
Transplant Proc; 2001 May; 33(3):2315-6. PubMed ID: 11377543
[No Abstract] [Full Text] [Related]
7. Graft outcome in patients with biopsy-proven chronic renal allograft rejection.
Peddi VR; Schroeder TJ; Weiskittel P; First MR
Transplant Proc; 1999; 31(1-2):1308-9. PubMed ID: 10083584
[No Abstract] [Full Text] [Related]
8. Reduced severity of acute rejection in hepatitis C virus positive renal allograft recipients: are milder immunosuppressive regimens advisable?
Pascual J; Crespo M; Mateos ML; Marcén R; Orofino L; Burgos FJ; Liaño F; Ortuño J
Transplant Proc; 1998 Jun; 30(4):1329-30. PubMed ID: 9636540
[No Abstract] [Full Text] [Related]
9. Long-term efficacy of OKT3 for steroid-resistant acute rejection in renal transplant patients.
Kumano K; Irie A; Mashimo S; Endo T; Koshiba K
Transplant Proc; 1996 Jun; 28(3):1354-5. PubMed ID: 8658691
[No Abstract] [Full Text] [Related]
10. Induction of immunosuppression with OKT3 following heart transplantation: kidney function as a criterion for control of protocol duration.
Rodríguez JA; Crespo-Leiro MG; Paniagua MJ; Muñiz J; Hermida LF; Fojón S; Cuenca JJ; Juffé-Stein A; Castro-Beiras A
Transplant Proc; 1999 Sep; 31(6):2517-8. PubMed ID: 10500696
[No Abstract] [Full Text] [Related]
11. Induction therapy for pediatric and adult heart transplantation: comparison between OKT3 and daclizumab.
Chin C; Pittson S; Luikart H; Bernstein D; Robbins R; Reitz B; Oyer P; Valantine H
Transplantation; 2005 Aug; 80(4):477-81. PubMed ID: 16123721
[TBL] [Abstract][Full Text] [Related]
12. Impact of OKT3 treatment for steroid resistant rejection of renal allografts: the long-term outcome at a single center.
Inui M; Tanabe K; Ishikawa N; Tokumoto T; Harano M; Otsubo S; Suzuki K; Goya N; Yagisawa T; Nakazawa H; Fuchinoue S; Toma H
Transplant Proc; 1999 Nov; 31(7):2870-1. PubMed ID: 10578320
[No Abstract] [Full Text] [Related]
13. Immunosuppression for recipients of kidneys from non-heart-beating donors: comparison of triple therapy and OKT3 regimens.
Kehinde EO; Wheatley T; Feehally J; Nicholson ML; Veitch PS; Bell PR
Transplant Proc; 1996 Jun; 28(3):1338-9. PubMed ID: 8658684
[No Abstract] [Full Text] [Related]
14. Induction immunosuppression in kidney transplant recipients older than 60 years of age : safety and efficacy of ATGAM, OKT3 and Simulect.
Heifets M; Saeed MI; Parikh MH; Sierka D; Kumar MS
Drugs Aging; 2004; 21(11):747-56. PubMed ID: 15323580
[TBL] [Abstract][Full Text] [Related]
15. Outcomes in recipients of combined heart-kidney transplantation: multiorgan, same-donor transplant study of the International Society of Heart and Lung Transplantation/United Network for Organ Sharing Scientific Registry.
Narula J; Bennett LE; DiSalvo T; Hosenpud JD; Semigran MJ; Dec GW
Transplantation; 1997 Mar; 63(6):861-7. PubMed ID: 9089227
[TBL] [Abstract][Full Text] [Related]
16. Review and preview of anti-T-cell antibodies.
Helderman JH
Transplant Proc; 1995 Oct; 27(5 Suppl 1):8-9. PubMed ID: 7482824
[No Abstract] [Full Text] [Related]
17. Impact of cyclosporine dose on long-term outcome after heart transplantation.
Valantine H; Hunt S; Gamberg P; Miller J; Luikart H
Transplant Proc; 1994 Oct; 26(5):2710-2. PubMed ID: 7940848
[No Abstract] [Full Text] [Related]
18. Treatment of steroid resistant rejection following renal transplantation: benefits and risks of OKT3 therapy.
Kehinde EO; Feehally J; Scriven SD; Veitch PS; Bell PR
Transplant Proc; 1996 Jun; 28(3):1449-50. PubMed ID: 8658735
[No Abstract] [Full Text] [Related]
19. ATG versus OKT3 in the treatment of steroid-resistant rejection following living-related donor renal transplantation.
Uslu A; Tokat Y; Ok E; Unsal A; Ilkgul O; Kaplan H
Transplant Proc; 1997 Nov; 29(7):2805-6. PubMed ID: 9365571
[No Abstract] [Full Text] [Related]
20. Early cyclosporine blood levels impact the incidence of acute rejection and overall mortality in the first year after heart transplantation.
Gómez-Sánchez MA; Delgado JF; Escribano P; Santos M; Sotelo T; Gil R; Hernández-Afonso J; Ortuño B; Romero F; Sáenz de la Calzada C; Rodriguez JE; Rufilanchas JJ
Transplant Proc; 1998 Aug; 30(5):1671-2. PubMed ID: 9723237
[No Abstract] [Full Text] [Related]
[Next] [New Search]
